By discovering how the antifibrotic treatments Ofev (nintedanib) and Esbriet (pirfenidone) work, researchers hope to develop even better drugs to…
Articles by Magdalena Kegel
Shorter telomeres — the DNA regions that protect the ends of chromosomes — are linked to lower survival rates in…
A molecular cascade that prompts stem cells used in lung transplants to drive fibrotic processes is responsible for the low survival…
Researchers discovered a molecule that promotes lung fibrosis by integrating large amounts of data from patients, cell experiments, and animal models.
Measuring disease-associated factors in sputum may be a less invasive way of tracking molecular changes in idiopathic pulmonary fibrosis (IPF)…
Patients with idiopathic pulmonary fibrosis (IPF) who rapidly gain weight may have a poorer prognosis than those with lesser weight…
A lung fibrosis treatment based on a shark antibody is on the verge of entering a first clinical trial in patients. The treatment…
By developing a drug that blocks a molecule — going under the curious name, porcupine — Redx Pharma hopes…
A case report illustrates the possibility of treating cancer patients who develop bleomycin-triggered lung disease with Esbriet (pirfenidone) — a…
The immune factor CCL8 could be a diagnostic marker of idiopathic pulmonary fibrosis (IPF), and it might be useful in…